PROPANC BIOPHARMA, INC.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | — | — | — | $4.1K | $2.3K | $67.0K | — | — |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $8.4M | $25.4K | $19.0K | $15.0K | $6.6K | $69.0K | $91.1K | $60.9K |
| Property, Plant & Equipment | — | — | $302 | $2.0K | $4.3K | $5.7K | $8.4K | $8.3K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $19.6M | $72.4K | $60.3K | $81.7K | $13.1K | $98.5K | $101.7K | $71.4K |
| Liabilities | ||||||||
| Accounts Payable | $1.2M | $1.2M | $966.7K | $943.0K | $1.0M | $842.2K | $917.3K | $1.2M |
| Total Current Liabilities | $5.6M | $3.8M | $3.2M | $3.1M | $3.1M | $3.7M | $4.4M | $6.8M |
| Long-Term Debt | $537.9K | $399.3K | $390.5K | $926.4K | $624.6K | $1.6M | $1.7M | $4.7M |
| Total Liabilities | $5.7M | $3.9M | $3.2M | $3.1M | $3.1M | $3.7M | $4.4M | $6.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-125.6M | $-66.7M | $-64.7M | $-61.6M | $-58.2M | $-55.8M | $-51.0M | $-45.3M |
| Total Stockholders' Equity | $13.9M | $-3.8M | $-3.1M | $-3.0M | $-3.1M | $-3.6M | $-4.3M | $-6.8M |